Report: Padres willing to deal Hunter Renfroe

Getty Images

Kevin Acee of the San Diego Union-Tribune reports that the Padres “are willing to part with” Hunter Renfroe. In fact, he says “virtually every position player” on the Padres except for Manny Machado, Eric Hosmer and Fernando Tatis Jr. “can be had.” Renfroe, though, seems to be a likely trade candidate, he says.

Renfroe might not have a long-term fit in San Diego given that they have a number of outfield options but he might be attractive for a contender lacking on outfield power. He has hit 26 homers each of the last two seasons and already has 18 homers in 2019. The on-base percentage is not good — .291 at the moment and that’s pretty much where he always is — but pop is pop, right? He’s also under team control through 2023.

The Padres are in fourth place in the NL West, 13 games back of the Dodgers. That’s not necessarily shocking as, despite all of their offseason moves and their young talent, they seemed to be at least a year away regardless. Why not try to leverage whatever they can in order improve for the long term.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.